← boardnext 2026-12next 2027-04
IXHL
Incannex Healthcare Ltddistress 3/10 · well-funded / low risk$3.110%today-94% from 52w high
Lead: obstructive sleep apnea
Revenue
pre-revenue
Liquidity
$74M
Runway
6.0 yrs
Shares 1y
-97%
Price & events
-71.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
-1.3%
1W
-6.0%
1M
-17.9%
3M
-69.9%
6M
-89.7%
1Y
-95.3%
2Y
—
5Y
-99.8%
All
Overview
- Market Cap
- $37.21M
- Enterprise Value
- $-34.86M
- Volume
- 10.64K
- 52 Week Range
- $2.56 – $48.90
- Total Shares
- 11.96M
- Float Shares
- 9.87M
- Short %
- 4.31%
- % Held by Insiders
- 12.34%
- % Held by Institutions
- 12.09%
- RVOL
- 0.04x
- Beta
- 2.79
Pipeline stages · 2 programs
IHL-42X Low Dose, IHL-42X High Dose, IHL-42X (Optimal Dose)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IHL-42X: 2.5 mg dronabinol, 125 mg acetazolamide, IHL-42X: 5 mg dronabinol
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 2/3 | IHL-42X Low Dose, IHL-42X High Dose, IHL-42X (Optimal Dose) | Obstructive Sleep Apnea | — | active not recruiting |
| 2027-04 Estimated 50% readout ~2027-05-16 | Phase 2 | IHL-42X: 2.5 mg dronabinol, 125 mg acetazolamide, IHL-42X: 5 mg dronabinolfast track | Obstructive Sleep Apnea (OSA) | — | not yet recruiting |
Catalyst news & presentations · 7
- second half of 2027Guided 55%trial initiationsecondaryPhase 3IHL-42X · Anticipated Phase 3 development start.SEC 8-K
- July 23, 2026trial initiationsecondaryPhase 2IHL-42X · Participant screening commenced in DReAMzz Phase 2 dose confirmation study of IHL-42X for obstructive sleep apnea.SEC 8-K
- May 14, 2026trial initiationsecondaryIHL-42X · Official commencement of DReAMzz crossover dose optimization study to refine IHL-42X dosing and support Phase III design.SEC 8-K
- 2026-03-25partnershipIHL-42X · Entered into Partnership Agreement with AASM Foundation; joined Corporate Recognition Program and will sponsor Focused Projects Grant for Junior InvestigatorsSEC 8-K
- later in the yeartrial initiationsecondaryPhase 3IHL-42X · Phase 3 U.S. study initiationSEC 8-K
- July 2025readoutPhase 2IHL-42X · Topline data readout from Phase 2 RePOSA trialSEC 8-K
- 2025-05-29fda agreementIHL-42X · FDA reviewed and authorized Phase 3 protocol under IND for IHL-42X in OSASEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $18 (+465% upside) · 1 analysts
- 2026-06-08Alliance Global PartnersBuy
Competitors — obstructive sleep apnea
Recent news
- 2026-07-23Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea - The Manila Times
- 2026-07-23Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea - GlobeNewswire
- 2026-07-23Incannex Commences Screening in Phase 2 DReAMzz Study of IHL-42X for OSA - TradingView
- 2026-07-18Why Did IXHL Stock Tank Over 32% Today? - Stocktwits
- 2026-07-17IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms - Stocktwits
- 2026-07-16Incannex Secures US Patent for Sleep Apnea Drug Candidate IHL-42X - Sleep Review
- 2026-07-15Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X - Yahoo Finance
- 2026-07-04Price to book forward of Incannex Healthcare Inc. – NASDAQ:IXHL - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.